Walleye Capital LLC bought a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 131,667 shares of the company's stock, valued at approximately $1,095,000.
Other institutional investors have also recently bought and sold shares of the company. Rothschild Investment LLC bought a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth about $26,000. Gladius Capital Management LP bought a new position in Amneal Pharmaceuticals during the third quarter worth about $37,000. DekaBank Deutsche Girozentrale acquired a new stake in Amneal Pharmaceuticals during the second quarter valued at approximately $42,000. nVerses Capital LLC bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at approximately $62,000. Finally, Xponance Inc. acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $65,000. Institutional investors and hedge funds own 31.82% of the company's stock.
Amneal Pharmaceuticals Trading Down 2.1 %
Shares of Amneal Pharmaceuticals stock traded down $0.18 during trading on Friday, reaching $8.45. The company's stock had a trading volume of 1,139,194 shares, compared to its average volume of 1,395,339. The stock has a 50-day moving average price of $8.55 and a two-hundred day moving average price of $7.84. The stock has a market capitalization of $2.62 billion, a P/E ratio of -12.43 and a beta of 1.12. Amneal Pharmaceuticals, Inc. has a one year low of $4.46 and a one year high of $9.48.
Insider Transactions at Amneal Pharmaceuticals
In related news, SVP Jason B. Daly sold 43,657 shares of the firm's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the transaction, the senior vice president now owns 13,665 shares in the company, valued at $117,655.65. This trade represents a 76.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 26.56% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Several analysts recently commented on AMRX shares. Barclays boosted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an "overweight" rating in a research note on Tuesday, August 13th. Piper Sandler boosted their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. StockNews.com upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Monday, November 11th. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price target on the stock in a research report on Friday, September 6th. Finally, Truist Financial upped their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Wednesday, October 2nd. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $10.00.
Get Our Latest Stock Report on AMRX
About Amneal Pharmaceuticals
(
Free Report)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Featured Stories
Before you consider Amneal Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.
While Amneal Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
